anoth miss guid cut big share
buyback bolster ep
cc sale growth miss ep ahead non-op
wat sale street bofaml est
constant currenc growth vs guid our/street expect fx
gm in-lin opm slightli ahead mix fx lead adj ep
vs street incl net benefit lower share count lower interest
expens tax-rat first look overview result
india remain soft weak eu pharma latest surpris
bit bounce-back wat result fell short everi categori
group despit strong data peer instrument consum key
geographi busi segment weakest link continu lag
recoveri india soft eu pharma new develop management indic
expect issu persist near-term result organ sale
guid inclus extra sell day view issu appear
wat-specif support long-term bearish view name
wildcard share buyback
organ growth stori continu lag peer expect major
bounce-back even increment product launch improv execut
aggress deploy capit bolster earn growth management guid
share buyback total total share
well rais debt level net leverag current net
cash posit impli new debt use share
buyback time debt rais buyback capit deploy
well specif deal pursu major swing-factor outlook
lower sale est rais adj ep
est due share buyback reiter
under-perform rate po base estimate in-lin compani yr
forward averag last yr still downsid risk organ growth
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
water face difficult market condit
product cycl share shift market
expect continu soft perform
view target ambiti believ
dynam take time play
share buyback may off-set earn
soft expect slower organ growth
lead under-perform rel peer
po base price-to-earnings estim in-lin histor
trade level past year back dcf analysi assum
wacc termin growth believ multipl justifi given
current growth profil peer-group valuat
slow china tariff/trad war escal weaker global economi share
loss competitor slowdown pharma biotech spend downsid
risk price object upsid risk po aggress capit
deploy faster expect uptak new product acquisit
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
